Contract Development and Manufacturing Organization (CDMO) Goodwin Biotechnology, which focuses on process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and biologic-drug conjugates including antibody-drug conjugates (ADCs) for early- and late-stage clinical trials through to commercial production, has confirmed the appointments of Brandon Price, Ph.D. and Kent Payne, Ph.D. to its Board of Directors.

“On behalf of the entire Board and Goodwin Biotechnology, I am delighted to welcome these distinguished and highly experienced individuals to our Board of Directors,” Karl Pinto, Chief Executive Officer of Goodwin Biotechnology, noted.

“Price has over 40 years of wide ranging experience in the biopharmaceutical industry covering all aspects of drug development, manufacturing, business, and management and incudes a stint as Goodwin’s CEO. and Payne has immense operational, strategic, and market knowledge stemming from more than 30 years of experience in the field. In the short time I’ve known Payne, he has come across as one of the most operationally astute, strongly networked, and helpful people that I have come across.”

MabPlex
ADC Bio
Lonza
 

Infrastructure
“Goodwin has the infrastructure, experience, and skilled scientists, cutting edge technologies, and flexibility to overcome and resolve Process Development and Manufacturing challenges of today’s complex biopharmaceuticals,” noted Price.

“This company is the right size with the appropriate compliance and manufacturing capacity for developing and manufacturing biopharmaceutical candidates cost effectively and in a timely manner,” Payne continued.

Price has been the co-founder of three academic institutes and five biotechnology companies and has extensive international experience. In the early 2000s Price served as CEO of Goodwin Biotechnology. He earned his Ph.D. in Biophysics from the University of Michigan.

Payne has also global experience where he helped grow Fortune 500 and Private Equity companies as well as startups. He combines strong business leadership and biotechnology expertise across biotechnology and pharmaceutical market segments and combined drug platforms including antibody-drug conjugates (ADCs). He earned his Ph.D. in Analytical Chemistry from Brigham Young University.

Price and Payne join Nikhil Puri of Signet Healthcare Partners, Divya Menezes, MD, and Karl Pinto to complete Goodwin’s Board of Directors.

“We have now put together a team of true industry professionals to guide Goodwin Biotechnology we scale into our future as an appropriately sized and equipped organization to efficiently handle today’s complex biopharmaceuticals and provide our clients with the ability to simplify their manufacturing supply chains with our Single Source Solution™ approach to our world class services,” Pinto concluded.